Abstract 84P
Background
To modify the tumor burden score (TBS) and to develop a comprehensive and practical prognostic scoring system among Chinese patients with colorectal liver metastases (CRLM).
Methods
787 adult patients who underwent curative-intent liver resection for CRLM were identified from Zhongshan Hospital in Shanghai, China between June 2010 and January 2018. Tumor relapse-free survival (RFS) was the main outcomes. TBS was modified with geometric algorithms. The Cox regression model was used to identify independent predictors of prognosis. Time-dependent AUC, calibration curve, and C-index were employed to validate the predictive ability of a survival model.
Results
Modified TBS (mTBS) was established by a mathematical equation (parameters were CRLM size, CRLM number, and unilobar/bilobar metastasis). mTBS model (AUC=0.62 at 33 Month) out-performed TBS model (AUC=0.54 at 33 Month) in predicting RFS (P=.002). Five preoperative predictors of worse RFS were identified and were incorporated into CERR score: KRAS/NRAS/BRAF mutated tumor (score 1 point); node-positive primary (1 point); extrahepatic disease (1 point); CEA level >200 ng/ml or CA 19-9 >200 U/mL (1 point); mTBS between 5 and 11 (1 point) or 12 and over (2 points). Patients undergoing hepatectomy for CRLM were stratified by CERR score into risk groups: high-risk group (CERR score 4 or more) had a 3-year RFS rate of 9.77%; medium-risk group (CERR score 2-3) had a 3-year RFS rate of 21.96%; low-risk group (CERR score 0-1) had a 3-year RFS rate of 39.90%. The CERR score model was further validated using internal bootstrap validation, and the discriminatory capacity of the CERR score was significantly superior to that of the Fong score and that of the Genetic and Morphological Evaluation (GAME) score.
Conclusions
Modified TBS should be promoted. The CERR score is a powerful prognostic tool that can help to determine the optimal clinical management strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract